PG-102
As of the edition of 20 October 2026, PG-102 is a drug: in active development; acts on CD40.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Unknown
- Registered trials
- 5, 1 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Bones, joints and muscles; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of PG-102.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD40 | Tumor necrosis factor receptor superfamily member 5 | P25942 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 3 | 0 | 3 | 0 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PanGenetics | Lead sponsor of trials | 2008 to now |
| Progen Pharmaceuticals | Lead sponsor of trials | 2024 to now |